prikaz prve stranice dokumenta Relative Change in S100 as a Biomarker of Survival in Patients With Metastatic Melanoma
No public access
Scientific paper - Original scientific paper
Relative Change in S100 as a Biomarker of Survival in Patients With Metastatic Melanoma
Anticancer Research, 40 (2020), 4; 2157-2163. https://doi.org/10.21873/anticanres.14175
Simetić, Luka; Blažević, Krešimir; Međugorac, Kata; Golčić, Marin; Herceg, Davorin

Institutional repository: Repository of the University of Rijeka, Faculty of Medicine

Cite this document

Simetić, L., Blažević, K., Međugorac, K., Golčić, M. & Herceg, D. (2020). Relative Change in S100 as a Biomarker of Survival in Patients With Metastatic Melanoma. Anticancer Research, 40. (4), 2157-2163. doi: 10.21873/anticanres.14175

Simetić, Luka, et al. "Relative Change in S100 as a Biomarker of Survival in Patients With Metastatic Melanoma." Anticancer Research, vol. 40, no. 4, 2020, pp. 2157-2163. https://doi.org/10.21873/anticanres.14175

Simetić, Luka, Krešimir Blažević, Kata Međugorac, Marin Golčić and Davorin Herceg. "Relative Change in S100 as a Biomarker of Survival in Patients With Metastatic Melanoma." Anticancer Research 40, no. 4 (2020): 2157-2163. https://doi.org/10.21873/anticanres.14175

Simetić, L., et al. (2020) 'Relative Change in S100 as a Biomarker of Survival in Patients With Metastatic Melanoma', Anticancer Research, 40(4), pp. 2157-2163. doi: 10.21873/anticanres.14175

Simetić L, Blažević K, Međugorac K, Golčić M, Herceg D. Relative Change in S100 as a Biomarker of Survival in Patients With Metastatic Melanoma. Anticancer Research [Internet]. 2020 [cited 2024 November 27];40(4):2157-2163. doi: 10.21873/anticanres.14175

L. Simetić, K. Blažević, K. Međugorac, M. Golčić and D. Herceg, "Relative Change in S100 as a Biomarker of Survival in Patients With Metastatic Melanoma", Anticancer Research, vol. 40, no. 4, pp. 2157-2163, 2020. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:392410. [Accessed: 27 November 2024]

Metadata
Title (english)Relative Change in S100 as a Biomarker of Survival in Patients With Metastatic Melanoma
Title (english)Relative Change in S100 as a Biomarker of Survival in Patients With Metastatic Melanoma Treated With Pembrolizumab
AuthorLuka Simetić
AuthorKrešimir Blažević
AuthorKata Međugorac
AuthorMarin Golčić https://orcid.org/0000-0002-3388-4813
AuthorDavorin Herceg
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Oncology and Radiotherapy)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Oncology
Abstract (english)
Background/Aim: There is a lack of quality biomarkers of survival for patients with metastatic melanoma treated with immunotherapy. Although the baseline level of S100 has prognostic value, its role during/after therapy in survival is unclear. Patients and Methods: We evaluated patients with metastatic melanoma treated with pembrolizumab with the goal of analysing the relationship between a relative change in S100 level at 12 weeks of immunotherapy and survival. Results: Patients with a relative change in S100 level >145% at 12 weeks of immunotherapy had significantly shorter progression-free (5.1 vs. 18.5 months, p≤0.0001) and overall survival (5.7 vs. 26.3 months, p<0.0001), further confirmed on multivariate analysis with hazard ratio of 32.25 (95% confidence interval=4.78–217.6, p=0.0004) for overall survival. Conclusion: A relative change in S100 level might be useful as a more precise biomarker of survival for patients with metastatic melanoma treated with pembrolizumab.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review - international
Publication versionPublished version
Journal titleAnticancer Research
Numberingvol. 40, no. 4, pp. 2157-2163
p-ISSN0250-7005
DOIhttps://doi.org/10.21873/anticanres.14175
URN:NBNurn:nbn:hr:184:392410
Publication2020
Document URLhttp://bib.irb.hr/1106867
Type of resourceText
Access conditionsClosed access
Terms of useLicence In copyright icon
Created on2022-03-07 14:18:56